|

9-valent HPV vaccine Clinical Trials

2 actively recruiting trials

No change since May 2026

Pipeline

Phase 3: 1Phase 4: 1

Top Sponsors

  • Zhejiang Provincial Center for Disease Control and Prevention1
  • Shanghai Bovax Biotechnology Co., Ltd.1

Indications

Other2 trials

Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
Phase 3
Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years
Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.